Impact of Acellular Pertussis Preschool Booster Vaccination on Disease Burden of Pertussis in The Netherlands

2008 ◽  
Vol 27 (3) ◽  
pp. 218-223 ◽  
Author(s):  
Sabine C. de Greeff ◽  
Frits R. Mooi ◽  
Joop F. P. Schellekens ◽  
Hester E. de Melker
Keyword(s):  
The Netherlands ◽  
Disease Burden ◽  
Booster Vaccination

scholarly journals Burden of foodborne disease in the Netherlands: from science to policy

2020 ◽  
Vol 30 (Supplement_5) ◽  
Author(s):  
L Mughini Gras
Keyword(s):  
Public Health ◽  
The Netherlands ◽  
Cost Of Illness ◽  
Disease Burden ◽  
Food Groups ◽  
Source Attribution ◽  
Productivity Losses ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Animal Contact

Abstract In the Netherlands, the Ministry of Health mandates the National Institute for Public Health and the Environment (RIVM) to provide annual updates of the number of illnesses, disease burden and cost-of-illness caused by an agreed-upon standard panel of 14 enteric pathogens. These pathogens are mainly transmitted by food, but also via direct contact with animals, environment-mediated and human-to-human transmission routes. The disease burden is expressed in DALYs (Disability Adjusted Life Years), a metric integrating morbidity and mortality into one unit. Furthermore, the cost-of-illness (COI) related to these 14 pathogens is estimated and expressed in euros. The COI estimates include healthcare costs, the costs for the patient and/or his family, such as travel expenses, as well as costs in other sectors, for example due to productivity losses. Moreover, using different approaches to source attribution, the estimated DALYs and associated COI estimates are attributed to five major transmission pathways (i.e. food, environment, direct animal contact, human-human transmission, and travel) and 11 food groups within the foodborne pathway itself. The most recent DALY and COI estimates referring to the year 2018 show that the 14 pathogens in question are cumulatively responsible for about 11,000 DALYs and €426 million costs for the Dutch population in 2018, with a share for foodborne transmission being estimated at 4,300 DALYs and €171 million costs, which is comparable to previous years. These estimates have been providing vital insights for policy making as to guide public health interventions and resource allocation for over two decades in the Netherlands. Herewith, the approach and outcomes of the burden of disease and COI estimates in the Netherlands will be presented, with a focus on how these estimates enable policy-makers and the scientific community to monitor trends, generate scientific hypotheses, and undertake public health actions.

scholarly journals Corrigendum to ‘Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom’

EBioMedicine ◽  
2021 ◽  
Vol 68 ◽  
pp. 103420
Author(s):  
Pauline Versteegen ◽  
Marta Valente Pinto ◽  
Alex M. Barkoff ◽  
Pieter G.M. van Gageldonk ◽  
Jan van de Kassteele ◽  
...  
Keyword(s):  
Older Adults ◽  
United Kingdom ◽  
The Netherlands ◽  
Collaborative Study ◽  
Booster Vaccination ◽  
The United Kingdom

Seroprevalence ofBordetella pertussisin the Mexican population: a cross-sectional study

2013 ◽  
Vol 142 (4) ◽  
pp. 706-713 ◽  
Author(s):  
C. CONDE-GLEZ ◽  
E. LAZCANO-PONCE ◽  
R. ROJAS ◽  
R. DeANTONIO ◽  
L. ROMANO-MAZZOTTI ◽  
...  
Keyword(s):  
Socioeconomic Status ◽  
Disease Burden ◽  
Public Health Intervention ◽  
Booster Vaccination ◽  
Cross Sectional Study ◽  
Serum Samples ◽  
Nutrition Survey ◽  
Cross Sectional ◽  
Health And Nutrition ◽  
Sources Of Infection

SUMMARYSerum samples collected during the National Health and Nutrition survey (ENSANUT 2006) were obtained from subjects aged 1–95 years (January–October 2010) and analysed to assess the seroprevalence ofBordetella pertussis(BP) in Mexico. Subjects' gender, age, geographical region and socioeconomic status were extracted from the survey and compiled into a subset database. A total of 3344 subjects (median age 29 years, range 1–95 years) were included in the analysis. Overall, BP seroprevalence was 47·4%. BP seroprevalence was significantly higher in males (53·4%,P = 0·0007) and highest in children (59·3%) decreasing with advancing age (P = 0·0008). BP seroprevalence was not significantly different between regions (P = 0·1918) and between subjects of socioeconomic status (P = 0·0808). Women, adolescents and young adults were identified as potential sources of infection to infants. Booster vaccination for adolescents and primary contacts (including mothers) for newborns and infants may provide an important public health intervention to reduce the disease burden.

scholarly journals Disease burden in The Netherlands due to infections with Shiga toxin-producing Escherichia coli O157

2004 ◽  
Vol 132 (3) ◽  
pp. 467-484 ◽  
Author(s):  
A. H. HAVELAAR ◽  
Y. T. H. P. VAN DUYNHOVEN ◽  
M. J. NAUTA ◽  
M. BOUWKNEGT ◽  
A. E. HEUVELINK ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
The Netherlands ◽  
Shiga Toxin ◽  
Disease Burden ◽  
Escherichia Coli O157

scholarly journals The estimated disease burden of norovirus in The Netherlands

2012 ◽  
Vol 141 (3) ◽  
pp. 496-506 ◽  
Author(s):  
L. VERHOEF ◽  
M. KOOPMANS ◽  
W. VAN PELT ◽  
E. DUIZER ◽  
J. HAAGSMA ◽  
...  
Keyword(s):  
General Practitioner ◽  
The Netherlands ◽  
Disease Burden ◽  
Age Distribution ◽  
Case Fatality ◽  
Disability Adjusted Life Years ◽  
The Past ◽  
Disease Outcomes ◽  
Disability Adjusted Life ◽  
Life Years

SUMMARYNoroviruses are an important cause of acute gastroenteritis in humans. We incorporated new insights gained over the past decade in an updated estimate of the disease burden of (foodborne) norovirus illness in The Netherlands in 2009. The disease outcomes – non-consulting cases, visiting a general practitioner, hospitalization and mortality – and the foodborne proportion were derived from cohort studies, surveillance data and literature. Age-specific incidence estimates were applied to the population age distribution in The Netherlands in 2009. The general population incidence was 3800/100 000 (95% CI 2670–5460), including 0·4 fatal cases/100 000, resulting in 1622/100 000 (95% CI 966–2650) disability-adjusted life-years in a population of 16·5 million. The updated burden of norovirus is over twofold higher than previously estimated, due in particular to the new insights in case-fatality ratios. Results suggest that the burden of norovirus institutional outbreaks is relatively small compared to the burden of community-acquired norovirus infections.

scholarly journals Disease burden of foodborne pathogens in the Netherlands, 2009

2012 ◽  
Vol 156 (3) ◽  
pp. 231-238 ◽  
Author(s):  
Arie H. Havelaar ◽  
Juanita A. Haagsma ◽  
Marie-Josée J. Mangen ◽  
Jeanet M. Kemmeren ◽  
Linda P.B. Verhoef ◽  
...  
Keyword(s):  
The Netherlands ◽  
Foodborne Pathogens ◽  
Disease Burden

Cost of Illness and Disease Burden in The Netherlands Due to Infections with Shiga Toxin–Producing Escherichia coli O157

2011 ◽  
Vol 74 (4) ◽  
pp. 545-552 ◽  
Author(s):  
LUQMAN TARIQ ◽  
JUANITA HAAGSMA ◽  
ARIE HAVELAAR
Keyword(s):  
Escherichia Coli ◽  
Health Care ◽  
The Netherlands ◽  
Health Care Costs ◽  
Cost Of Illness ◽  
Shiga Toxin ◽  
Disease Burden ◽  
Escherichia Coli O157 ◽  
Discounted Costs ◽  
Care Costs

Infections with Shiga toxin–producing Escherichia coli O157 (STEC O157) are associated with hemorrhagic colitis, hemolytic uremic syndrome (HUS), and end-stage renal disease (ESRD). In the present study, we extend previous estimates of the burden of disease associated with STEC O157 with estimates of the associated cost of illness in The Netherlands. A second-order stochastic simulation model was used to calculate disease burden as disability-adjusted life years (DALYs) and cost of illness (including direct health care costs and indirect non–health care costs). Future burden and costs are presented undiscounted and discounted at annual percentages of 1.5 and 4%, respectively. Annually, approximately 2.100 persons per year experience symptoms of gastroenteritis, leading to 22 cases of HUS and 3 cases of ESRD. The disease burden at the population level was estimated at 133 DALYs (87 DALYs discounted) per year. Total annual undiscounted and discounted costs of illness due to STEC O157 infection for the Dutch society were estimated at €9.1 million and €4.5 million, respectively. Average lifetime undiscounted and discounted costs per case were both €126 for diarrheal illness, both €25,713 for HUS, and €2.76 million and €1.22 million, respectively, for ESRD. The undiscounted and discounted costs per case of diarrheal disease including sequelae were €4,132 and €2,131 , respectively. Compared with other foodborne pathogens, STEC O157 infections result in relatively low burden and low annual costs at the societal level, but the burden and costs per case are high.

scholarly journals Reasonable Grounds? The Delayed Introduction of MMR Vaccine in Denmark and the Netherlands, 1977–87

2020 ◽  
Vol 64 (3) ◽  
pp. 355-373
Author(s):  
Anne Hagen Berg ◽  
Stuart S. Blume
Keyword(s):  
The Netherlands ◽  
Disease Burden ◽  
Welfare States ◽  
Costs And Benefits ◽  
Mmr Vaccine ◽  
International Context ◽  
Vaccine Introduction ◽  
National Immunisation ◽  
Complex Picture ◽  
The Usa

It is commonly argued that the decision to introduce a new vaccine is properly based on objective and measurable criteria, including disease burden and efficacy of the vaccine. Moreover, new vaccines are to be introduced rapidly and globally: delay is difficult to justify. Historical studies of new vaccine introductions paint a rather different and more complex picture. The few studies comparing new vaccine introduction in different countries suggest that ‘evidence’ for the efficacy of a vaccine was commonly subjected to varying interpretations. This paper, based on analysis of the introduction of the measles–mumps–rubella (MMR) vaccine in Denmark and the Netherlands, takes this argument further. Though both countries are – and were – small welfare states with well-organised national immunisation programmes, both adopted MMR a full decade after its introduction in the USA. The paper suggests that the reasons for delaying, in each case, are a reasonable reflection of each country’s concerns, perceptions of the three diseases, and technological approaches already adopted. There were differences in each of these respects. The decision to adopt MMR, which each country eventually took, was significantly influenced by the political and ideological changes taking place in the 1980s, including a growing emphasis on costs and benefits, as well as the growing influence of the international context.

Sign in / Sign up

Export Citation Format

Share Document